regarding fdc from current levels downsides seem limited… But triggers for upmove also dont seem to be forthcoming… growth seems slow in terms of sales and profits. Company is loaded with cash and doesnt seem to know what to do with it.
Unichem results expectedly were lacklustre. regarding dividends from proceeds from devas sez I dont think there will be special dividends. management has mentioned that they would utilise this fund to augment capacities at goa plant.
No canfin homes in portfolio is asurpriseto me . any reasons ? Recently i read aboutBangaloreproperty market and sales there are much better than q1 , can fin home is very large nbfc there.
I have a query. As you have already mentioned that kaveri mainly delivers in first quarter i.e.next june qtr which is a few quarters away then why can’t we deploy the cash in any better opportunity which has a greater potential of providing returns early and start buying Kaveri fropm the onset of next year 1st quarter to maximize returns.
Please note that this is just to understand the rationale so that I can improve my own understanding.
kaveri currently looks attractive based on its fy 14 projections… the recent correction seems mainly on fears of lacklustre three quarters post a stellar first quarter… And maybe the overhang of rumours/news of selling by idfc etc may also be playing out…
For stocks to correct/consolidate, a number of reasons will be put forward… I consider most of it as noise… At the end of day stock prices always tend to follow earnings.
Based on fy 14 estimates of 125-130 per share, kaveri currently is available at a PE of 12-13 times… And this for a company which has grown 40% cagr in last five years and with a debt free balance sheet.
Nice to see someone like you being on the same page,as regards Biocon.I myself made an entry into Biocon.The excitement about its new drug AlzumAb waned out pretty fast…looks good.Any estimates on results? I would consider anything above 110cr. as excellent
And don’t you like anything in the Teck space? Or avoiding it coz its ‘overheated’?
biocon… I like the chart pattern better than the actual fundamentals… Maybe fundamentals will follow technicals… they do have a good presence in insulins and statins… Annual report describes a rosy picture and now it needs to be seen how they deliver.
tech pack I missed the whole rally and now dont feel the urge to enter now.